IA期非小细胞肺癌的肺叶特异性淋巴结清扫:回顾性队列研究
该回顾性队列研究分析了2005年6月至2017年4月在韩国首尔峨山医疗中心接受肺叶切除和系统性淋巴结清扫的1202例临床IA期非小细胞肺癌患者,按肿瘤所在肺叶分组评估淋巴结转移规律及肺叶特异性淋巴结清扫对生存的影响。研究发现各肺叶5年总生存率为74%至88%,非肺叶特异性淋巴结转移发生率约1%,支持在IA期NSCLC中采用肺叶特异性淋巴结清扫。
要点
- IA期NSCLC各肺叶5年OS为74%至88%,单站淋巴结转移发生率10%至16%。
- 各肺叶特异性淋巴结站分别为:右上叶2/3/4、右中叶4/7、右下叶2/4/7、左上叶4/5/6、左下叶6/7/9。
- 高效指数站阴性时其他站转移可能性低,非特异性站转移率约1%。
核心结论
- 研究结果支持在IA期非小细胞肺癌中采用肺叶特异性淋巴结清扫。
- 当高效指数淋巴结站阴性时,其他站淋巴结转移可能性低。
- 非肺叶特异性淋巴结转移发生率在所有亚组中约为1%,清扫非肺叶特异性淋巴结可能不改善总生存。
研究设计与样本
- 回顾性队列研究,纳入2005年6月至2017年4月韩国首尔峨山医疗中心1202例临床IA期NSCLC患者。
- 患者均接受肺叶切除和系统性淋巴结清扫,排除接受新辅助治疗、多原发肿瘤或术后第一年失访者。
- 按肿瘤所在肺叶分为右上叶、右中叶、右下叶、左上叶和左下叶五组,并进一步按淋巴结站转移分亚组。
主要发现
- 右上叶、右中叶、右下叶、左上叶和左下叶组5年总生存率分别为74%、88%、78%、80%和75%。
- 右上叶、右中叶、右下叶、左上叶和左下叶组单站淋巴结转移发生率分别为11%、10%、10%、16%和14%。
- 右上叶组2、3、4站转移发生率分别为2.3%、0.5%、7.6%,高效指数分别为0.8、0.3、4.3。
- 右中叶组4、7站转移发生率分别为4%、6%,高效指数分别为1.3、2.4;右下叶组2、4、7站转移发生率分别为4.4%、5.6%、8.3%,高效指数分别为1.3、1.4、3.3。
- 左上叶组4、5、6站转移发生率分别为1.4%、11.8%、2.5%,高效指数分别为0.4、7.1、0.5;左下叶组6、7、9站转移发生率分别为1.1%、5.7%、1.7%,高效指数分别为0.6、2.3、0.5。
关键数值与推荐
- 右上叶肺叶特异性淋巴结站为2/3/4,高效指数站为4。
- 右中叶肺叶特异性淋巴结站为4/7,高效指数站为7。
- 右下叶肺叶特异性淋巴结站为2/4/7,高效指数站为7。
- 左上叶肺叶特异性淋巴结站为4/5/6,高效指数站为5。
- 左下叶肺叶特异性淋巴结站为6/7/9,高效指数站为7。
临床怎么用
- 对于IA期NSCLC,可根据肿瘤所在肺叶选择性清扫肺叶特异性淋巴结站。
- 当高效指数站阴性时,可考虑省略非肺叶特异性淋巴结站的清扫。
- 肺叶特异性淋巴结转移患者的OS与非肺叶特异性淋巴结转移组有统计学显著差异(P值:右上叶<0.001,右中叶0.002,右下叶0.002,左上叶0.001,左下叶0.003)。
局限性
- 本研究为回顾性队列研究,存在选择偏倚等固有局限。
- 结论需前瞻性随机对照试验验证以修改标准术式。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate lymph node (LN) metastasis according to tumour location and assess the impact of lobe-specific LN dissection on survival in stage IA non-small-cell lung cancer (NSCLC). METHODS: We retrospectively analysed the data of patients with clinical stage IA NSCLC treated with lobectomy and systematic LN dissection at Asan Medical Center (Seoul, Korea) between June 2005 and April 2017. Patients who received neoadjuvant therapy had multiple primary tumours or missed the follow-up during the first postoperative year were excluded. The patients were divided into five groups according to involved lung lobes: right upper lobe (RUL), right middle lobe (RML), right lower lobe (RLL), left upper lobe (LUL) and left lower lobe (LLL), which were further divided into subgroups according to LN station metastasis. Overall survival (OS) and the incidence of metastasis were calculated for each subgroup. Efficacy indices (EIs) were calculated to determine the correlation between each lung lobe and LN station, and the impact of the dissection of these stations on survival. RESULTS: A total of 1202 patients were analysed. The 5-year OS in the RUL, RML, RLL, LUL and LLL groups was 74%, 88%, 78%, 80% and 75%, respectively. The incidence of single LN station metastasis was 11%, 10%, 10%, 16% and 14%, respectively. The lobe-specific LNs for RUL, RML, RLL, LUL and LLL were stations 2/3/4, 4/7, 2/4/7, 4/5/6 and 6/7/9, respectively. Moreover, the LN stations with high EIs for RUL, RML, RLL, LUL and LLL were 4, 7, 7, 5 and 7, respectively. In the RUL group, the incidence of metastasis to stations 2, 3 and 4 was 2.3%, 0.5% and 7.6%, and the EI was 0.8, 0.3 and 4.3, respectively. In RML, the incidence of metastasis to stations 4 and 7 was 4% and 6%, and the EI was 1.3 and 2.4, respectively. In RLL, the incidence of metastasis to stations 2, 4 and 7 was 4.4%, 5.6% and 8.3%, and the EI was 1.3, 1.4 and 3.3, respectively. In LUL, the incidence of metastasis to stations 4, 5 and 6 was 1.4%, 11.8% and 2.5%, and the EI was 0.4, 7.1 and 0.5, respectively. In LLL, the incidence of metastasis to stations 6, 7 and 9 was 1.1%, 5.7% and 1.7%, and the EI was 0.6, 2.3 and 0.5, respectively. Furthermore, the OS of patients with lobe-specific LN metastasis was statistically significantly different from that of the non-lobe-specific LN metastasis group with P-values of <0.001 for RUL, 0.002 for RML, 0.002 for RLL, 0.001 for LUL and 0.003 for LLL. CONCLUSIONS: Our findings support the use of lobe-specific LN dissection in stage IA NSCLC. When LN stations with high EI were negative, LN metastasis in other stations was unlikely. The incidence of LN metastasis beyond lobe-specific LN stations was ∼1% in all subgroups. Dissection of non-lobe-specific LNs may not improve the OS; however, prospective randomized controlled trials are needed to modify the standard approach.
引用
- Abughararah TZ, Jeong YH, Alabbood F, et al. Lobe-specific lymph node dissection in stage IA non-small-cell lung cancer: a retrospective cohort study. Eur J Cardiothorac Surg. 2021. PMID: 33150427. doi:10.1093/ejcts/ezaa369
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。